{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4N-14boJDA","lastupdate":"2024-11-25T00:00:00.000Z","update_date":"2024-11-25T00:00:00.000Z","lastModified":"Oct 30, 2025","active":1,"confidence_score":96,"confidence_score_reason":"video or image, funding rounds, markets","urlname":"revium-rx","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$j3uaR7oLoBSjsdSH3URMfvzvcMIxzkupQkTwF40JIwix5T9VYVvlqx.jpeg","name":"Revium Rx","oneliner":"Advanced Lipid-based Platform","registrar":"516211141","website":"https://www.reviumrx.com","careerspage":"","founded_month":6,"founded_year":2021,"formernames":["Revium Recovery Inc."],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/106169093","instagram":""},"social":["https://www.linkedin.com/company/106169093"],"flattenedsociallinks":"https://www.linkedin.com/company/106169093","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"1-10","employees_exact":4,"patent":1,"raised":0,"stage":"Pre-Funding","public_stage":"Pre-Funding","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["ReviumRX"],"about":"Revium Rx develops advanced delivery systems for a variety of indications. Its platform expands the therapeutic horizons of hard-to-treat diseases by enhancing, improving and unleashing the potential of encapsulated therapeutics. Revium’s current pipeline encompasses antibiotics for antimicrobial-resistant bacteria, immune checkpoint inhibitor adjuvant for solid tumors, and a novel immunization platform.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"0018005191687","country":null,"address":{"israeli":[{"id":"225e8a55-a416-44f0-99c9-dafa74ac089a","city":"Herzliya","type":null,"address":"HaMenofim Street 10, Herzliya, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"YBSvErPPSAdEVJR1DFkucdzXqInqo1sj1Vu2iMe89DgEciLF0mGHCN","date":"Mar 31, 2025","link":"https://www.calcalistech.com/ctechnews/article/s1gk2pdajl","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"antibiotic resistance","round":null,"company":"Revium Rx","layoffs":null,"summary":"Revium Rx, a US-based pharmaceutical startup, has acquired LipoVation Ltd., an Israeli company specializing in lipid-based nanoparticle medicines. This acquisition positions Revium Rx at the forefront of nanoparticle-based therapeutics, particularly in addressing antibiotic resistance. The company is developing Nano-Mupirocin, a new formulation of an effective antibiotic, to combat multi-drug-resistant bacteria. The acquisition also involves a management change, with Inna Martin appointed as President and COO. Revium Rx is preparing for Phase I clinical trials of Nano-Mupirocin, expected to begin in early 2026. The global market for antibiotics targeting resistant bacteria is projected to grow significantly, highlighting the potential impact of Revium Rxs innovations.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["antibiotic resistance","nanoparticles","clinical trials","hospital infections","market potential"],"date_of_event":"2023","product_stage":"preclinical","investment_date":null,"acquired_company":"LipoVation Ltd.","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition","Management Changes","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Acquisition  #Management Changes  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"v3DgY3R7Vr87jJSoLVkuVc15JRE1iEDLliFfXCq5dXLQSUyIIdtu7Y","news_summary":"Revium Rx’s Nanoparticle Technology Aims to Tackle Antibiotic Resistance and Beyond | CTech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Qhxd298gab73aJjB7rk1bUvOBzYEdTSkHB6dGmZVqCTpZ9vc591SVG","date":"Feb 25, 2025","link":"https://www.calcalist.co.il/article/bjvnaqo91g","source":"www.calcalist.co.il","visible":1,"analysis":{"tags":"antibiotic development","round":null,"company":"Revium Rx","layoffs":null,"summary":"Revium Rx, in collaboration with Professor Hazi Barenholz from the Hebrew University of Jerusalem, is developing a novel antibiotic delivery system using nano-liposomes to combat antibiotic-resistant bacteria. Their innovative product, Nano-Mupirocin, aims to treat life-threatening infections with fewer side effects and reduced bacterial resistance. The company is advancing towards clinical trials, with Phase I trials expected to begin soon. The development has shown promising results in pre-clinical studies, particularly against resistant strains like MRSA and VRE. Revium Rx is also seeking additional funding from government and global projects to support their efforts. This advancement could significantly impact global healthcare by providing new solutions to antibiotic resistance.","partners":"Hebrew University of Jerusalem","customers":null,"eventType":null,"investors":"NIH","confidence":9,"key_topics":["antibiotic resistance","nano-liposomes","clinical trials","nanotechnology","healthcare innovation"],"date_of_event":"2023","product_stage":"pre-clinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"f0jplRtZk6yhNyUhNwFlWYujWUYIecM5akRkd9FvNYeo0HwKMGy5WN","news_summary":"המאבק בחיידקים עמידים לאנטיביוטיקה: \"פיתוח ישראלי חדש עשוי לעזור בטיפול בזיהומים מסכני חיים” | כלכליסט","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"T7UVArICo3HEGwEsmFqn9yWR2s7q0KpdP1FjfSqEanlUP4BSU3bDUO","date":"Feb 4, 2025","link":"https://csimarket.com/news/revium_rx_s_bold_acquisition_of_lipovation_ltd_a_game-changer_in_nanoparticle_drug_development_2025-02-04193208","source":"csimarket.com","visible":1,"analysis":{"tags":"acquisition","round":null,"company":"Revium Rx","layoffs":null,"summary":"Revium Rx has acquired LipoVation Ltd., a company known for its nanoparticle-based drug development. This acquisition marks a strategic shift for Revium Rx towards advanced drug delivery systems, enhancing its product pipeline and positioning it competitively in the biotechnology sector. The integration of LipoVations expertise is expected to positively impact Revium Rxs financial performance and market positioning, potentially leading to lucrative partnerships and clinical trials. The move aligns with global trends towards personalized medicine and could result in breakthroughs for chronic disease treatments. Market analysts anticipate a favorable trajectory for Revium Rxs share value as a result of this acquisition.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["nanoparticle","acquisition","biotechnology","drug development","market positioning"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":"LipoVation Ltd.","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"b450nj1FXDT91MZQbKTKD4g2BwyiL1NruJmckXGM3VvgZsVHYVfIvJ","news_summary":" Revium Rxs Bold Acquisition of LipoVation Ltd.: A Game-Changer in Nanoparticle Drug Development!","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"oUSSzsezfYcTeauQ6FqIMX8ZpdnTr37hSp2cWoAAiSySSwODATIhZQ","date":"Feb 4, 2025","link":"https://www.globenewswire.com/news-release/2025/02/04/3020730/0/en/Revium-Rx-RVRC-Completes-Acquisition-of-LipoVation-Ltd.html","source":"www.globenewswire.com","visible":1,"analysis":{"date":"Mon Mar 24 2025","status":-1,"message":"","entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"Da0b62pQUXbX7OOtFveq6SD1opBJDNqNwLEDSeZol5oEluWdgjC36i","news_summary":"Revium Rx (RVRC) Completes Acquisition of LipoVation Ltd.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":4,"techcommunityinvolvement":null,"mediagallery":[],"tags":["cancer-therapy","therapeutics","immunotherapy","drug-delivery","pharmaceuticals"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"R&D","products":["Nano-Mupirocin, Novel adjuvant to solid tumor theraies "],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":0,"lastfunding":"Undisclosed","totalrounds":0,"fundingstage":"Pre-Funding","totalfunding":"Undisclosed","publicinvestors":0,"lastpublicfunding":null,"totalpublicrounds":0,"totalpublicfunding":0},"team":[{"name":"David Akunis","email":"","phone":"","gender":"Male","userid":"X8H7dc7tmGWDA3fI32nHJmJjTSYF91RxZEyzOZyqQ4KoBWbe2wjThY","bounced":false,"claimed":null,"founder":0,"urlname":"david-akunis-1","visible":1,"memberid":"t5VsrfPSlxe5xtWE2qsyPBlxXaa4uSYYHeTUzeym3HnUHaw5JkEb4U","position":"CEO","last_name":"Akunis","claimtoken":null,"first_name":"David","picturekey":"$QFB3wiacsieTnTtT0elA8eiEApphD5jfbH16LMrfKK8LeXf8qo3pAu.png","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/david-akunis007/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$QFB3wiacsieTnTtT0elA8eiEApphD5jfbH16LMrfKK8LeXf8qo3pAu.png","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Inna Martin","email":"inna.blitz@gmail.com","phone":"0524721272","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4OTf1J4KDA","bounced":false,"claimed":1,"founder":1,"urlname":"inna-martin-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgv__phwsM","position":"COO & President","last_name":"Martin","claimtoken":"624c47e374283e13690483f4480fbf3d29717f4e6dfecde2c58981c8288c2829","first_name":"Inna","picturekey":"$ZzmM12Z53va0VUhje6IVT9XmenwZiR8YDQN4x6z9DmpRER1wKDT3FW.jpeg","claimeddate":"2021-08-03","linkedinurl":"https://www.linkedin.com/in/inna-m-5395264/","unsubscribed":false,"is_activeuser":1,"additionalemail":"inna.martin@reviumrecovery.com","claimedemaildate":null,"initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$ZzmM12Z53va0VUhje6IVT9XmenwZiR8YDQN4x6z9DmpRER1wKDT3FW.jpeg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Erez  Koren","email":"erez.koren@reviumrecovery.com","phone":"","gender":"Male","userid":"XFPrYONiDeAMCKxKdyiYUeTbBIpvJL9gO5jZkfdnPeh3ysXAnjSGMl","bounced":false,"claimed":null,"founder":0,"urlname":"erez-koren-2","visible":1,"memberid":"vLZYpeadtxS54Im9OznowxQynwQQflszZJRPN5JuxZphpc3X4o8JfV","position":"CTO ","last_name":"Koren","claimtoken":"AWpT3kuGJmzEur4rQykXVU53FzTmbkefW0B1CCATqNJqsf3s8JlJfR","first_name":"Erez ","picturekey":"$qYvbGENciw17GbBGgc4vQi6f5ZEtVTRbYHRiROeqBOhmIIG9dcjRME.jpeg","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/erezkoren/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-11-25 18:43:17.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$qYvbGENciw17GbBGgc4vQi6f5ZEtVTRbYHRiROeqBOhmIIG9dcjRME.jpeg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Life Sciences & HealthTech","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNqyo8cLDA","fullname":"Yotam Maman"},"biverifydate":"2021-08-04T00:00:00.000Z","crunchbaseid":"","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Inna Martin","creator_email":"inna.blitz@gmail.com","createdate":"2021-08-03T00:00:00.000Z","biverification":"Yotam Maman","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"CGO3vyk3rNJuW0bF9G7ntGI6hhJaTaKzIH7JCqvFSTnaa75DEGgYJK","date":"Feb 2025","amount":"Undisclosed","source":"https://www.globenewswire.com/news-release/2025/02/04/3020730/0/en/Revium-Rx-RVRC-Completes-Acquisition-of-LipoVation-Ltd.html","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"acquiredcompany_mna":"Lipovation","acquiredcompany_mna_id":"dcXh59monCekrZmVXVAsKsbnPamc9wPYVFIPbGXspuZMPr7eQ1jQeS","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/company_page/lipovation","acquiredcompany_mna_logokey":"$2JXzUKifsDGcwV2bayd4iuoVY2AoR0WFHVoGUMN7f11ikEQLVtE6S4.jpeg","acquiredcompany_mna_urlname":"/company_page/lipovation","acquiredcompany_mna_homepage":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$2JXzUKifsDGcwV2bayd4iuoVY2AoR0WFHVoGUMN7f11ikEQLVtE6S4.jpeg","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"6/2021","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Revium Rx","logourl":"https://storage.googleapis.com/clean-finder-353810/$j3uaR7oLoBSjsdSH3URMfvzvcMIxzkupQkTwF40JIwix5T9VYVvlqx.jpeg","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$j3uaR7oLoBSjsdSH3URMfvzvcMIxzkupQkTwF40JIwix5T9VYVvlqx.jpeg","seoabout":"Revium Rx develops advanced delivery systems for a variety of indications. Its platform expands the therapeutic horizons of hard-to-treat diseases by enhan...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drug Delivery","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drug Delivery"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"}]}]}],"coreTechnology":[]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drug Delivery"],"coreTechnology":[],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Patients"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[{"id":"CGO3vyk3rNJuW0bF9G7ntGI6hhJaTaKzIH7JCqvFSTnaa75DEGgYJK","date":"Feb 2025","amount":"Undisclosed","source":"https://www.globenewswire.com/news-release/2025/02/04/3020730/0/en/Revium-Rx-RVRC-Completes-Acquisition-of-LipoVation-Ltd.html","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"acquiredcompany_mna":"Lipovation","acquiredcompany_mna_id":"dcXh59monCekrZmVXVAsKsbnPamc9wPYVFIPbGXspuZMPr7eQ1jQeS","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/company_page/lipovation","acquiredcompany_mna_logokey":"$2JXzUKifsDGcwV2bayd4iuoVY2AoR0WFHVoGUMN7f11ikEQLVtE6S4.jpeg","acquiredcompany_mna_urlname":"/company_page/lipovation","acquiredcompany_mna_homepage":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$2JXzUKifsDGcwV2bayd4iuoVY2AoR0WFHVoGUMN7f11ikEQLVtE6S4.jpeg","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"others":[]}}